Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688621's Days Payable is ranked worse than 88.43% of 925
companies
in the Drug Manufacturers industry
Industry Median: 88.75
vs SHSE:688621: 31.22
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sun-Novo Pharmaceutical Research Co Days Payable Chart
Beijing Sun-Novo Pharmaceutical Research Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Sun-Novo Pharmaceutical Research Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Sun-Novo Pharmaceutical Research Co Days Payable vs Drug Manufacturers Industry
Beijing Sun-Novo Pharmaceutical Research Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) has a Days Payable of 51.94 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. This is 69% above median its historical median of 30.73. Over the past decade, Beijing Sun-Novo Pharmaceutical Research Co's Days Payable has ranged from 22.76 to 40.59. According to the industry distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #818 out of 925 companies in the Drug Manufacturers industry, placing it in the top 88.4%.
Is Beijing Sun-Novo Pharmaceutical Research Co's Days Payable too high?
Beijing Sun-Novo Pharmaceutical Research Co's current Days Payable of 51.94 is 69% above median its 10-year median of 30.73. Over the past 10 years, this metric has ranged from a low of 22.76 to a high of 40.59. The Drug Manufacturers industry median Days Payable is 88.75. Beijing Sun-Novo Pharmaceutical Research Co's value of 51.94 is 41.5% below this industry median. Based on the distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #818 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beijing Sun-Novo Pharmaceutical Research Co has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beijing Sun-Novo Pharmaceutical Research Co's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Sun-Novo Pharmaceutical Research Co ranks #818 out of 925 companies for Days Payable. This places Beijing Sun-Novo Pharmaceutical Research Co in the lower half of its industry. The industry median Days Payable is 88.75. Beijing Sun-Novo Pharmaceutical Research Co's value of 51.94 is 41.5% below this benchmark. Historically, Beijing Sun-Novo Pharmaceutical Research Co's own Days Payable has ranged from 22.76 to 40.59 over the past decade. While the company's 10-year median is 30.73 vs. the industry median of 88.75, Beijing Sun-Novo Pharmaceutical Research Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Sun-Novo Pharmaceutical Research Co's current Days Payable of 51.94 is 41.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Beijing Sun-Novo Pharmaceutical Research Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Sun-Novo Pharmaceutical Research Co's current Days Payable is 51.94, which is 69% above median its own 10-year median of 30.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Sun-Novo Pharmaceutical Research Co stock overvalued right now?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) is currently considered Fairly Valued. The stock's GF Value™ is ¥72.20, compared to a current price of ¥65.50 — trading 9.3% below its estimated fair value. The current Days Payable is 51.94, which is 69% above median its 10-year median of 30.73 and 41.5% below the Drug Manufacturers industry median of 88.75. Beijing Sun-Novo Pharmaceutical Research Co's overall GF Score™ is 93/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621), the current Days Payable is 51.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Sun-Novo Pharmaceutical Research Co (SHSE:688621) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Sun-Novo Pharmaceutical Research Co stock appears to be undervalued.
The current stock price of ¥65.50 is trading 9.3% below its estimated GF Value™ of ¥72.20.
GuruFocus considers Beijing Sun-Novo Pharmaceutical Research Co to be Fairly Valued.
Key valuation signals for SHSE:688621:
Days Payable: 51.94 (69% above median its 10-year median of 30.73)
GF Value™: ¥72.20 vs. price of ¥65.50 (9.3% below fair value)
Industry Position: 41.5% below the Drug Manufacturers median (#818 of 925)
No single metric tells the full story. See the SHSE:688621 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Sun-Novo Pharmaceutical Research Co Ltd is engaged in providing professional research and development outsourcing services for pharmaceutical companies.
93GF Score
Get the complete analysis for SHSE:688621
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688621 has been successfully added to your 
